Emerging pathogenic respiratory  mycoplasma hominis  infections in lung transplant patients: time to reassesses it's role as a pathogen? by Spiller, Owen Bradley
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/100677/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
Spiller, Owen Bradley 2017. Emerging pathogenic respiratory mycoplasma hominis infections in
lung transplant patients: time to reassesses it's role as a pathogen? EBioMedicine 19 , pp. 8-9.
10.1016/j.ebiom.2017.05.002 file 
Publishers page: http://dx.doi.org/10.1016/j.ebiom.2017.05.002
<http://dx.doi.org/10.1016/j.ebiom.2017.05.002>
Please note: 
Changes made as a result of publishing processes such as copy-editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
Research Paper
Cardiothoracic Transplant RecipientMycoplasma hominis: AnUncommon
Infection with Probable Donor Transmission
Rahul Sampath a, Robin Patel a,b, Scott A. Cunningham b, Sana Arif c, Richard C. Daly d,
Andrew D. Badley a, Mark E. Wylam e,⁎
a Division of Infectious Diseases, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
b Clinical Microbiology Laboratory, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
c Duke University Medical School, Durham, NC 27708, USA
d Cardiovascular Surgery, Department of Surgery, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
e Division of Pulmonary and Critical Care Medicine, Department of Medicine, Rochester, MN 55905, USA
a b s t r a c ta r t i c l e i n f o
Article history:
Received 6 March 2017
Received in revised form 11 April 2017
Accepted 18 April 2017
Available online 19 April 2017
The role of infection with Mycoplasma hominis following cardiothoracic organ transplantation and its source of
transmission have not beenwell-deﬁned. Here,we identify and describe infectionwithM. hominis in patients fol-
lowing cardiothoracic organ transplantation after reviewing all cardiothoracic transplantations performed at our
center between 1998 and July 2015. We found seven previously unreported cases ofM. hominis culture positive
infection all ofwhompresentedwith pleuritis, surgical site infection, and/ormediastinitis. PCRwasused to estab-
lish thediagnosis in four cases. In two instances, paired single lung transplant recipientsmanifested infection, and
in one of these pairs, isolates were indistinguishable by multilocus sequence typing (MLST). To investigate the
prevalence ofM. hominis in the lower respiratory tract, we tested 178 bronchoalveolar lavage (BAL) ﬂuids collect-
ed from immunocompromised subjects for M. hominis by PCR; all were negative. Review of the literature re-
vealed an additional 15 cases of M. hominis in lung transplant recipients, most with similar clinical
presentations to our cases. We recommend that M. hominis should be considered in post-cardiothoracic trans-
plant infections presenting with pleuritis, surgical site infection, or mediastinitis.M. hominis PCR may facilitate
early diagnosis and prompt therapy. Evaluation for possible donor transmission should be considered.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Mycoplasma hominis (M. hominis) is a mollicute that colonizes the
urogenital tract and occasionally causes invasive disease. Extra-genital
infections with this organism occur primarily in immunosuppressed
persons.M. hominishas been linked to pregnancy-related complications
and causes meningitis and pneumonia in neonates (Cassell et al., 1991;
Samra et al., 2002; Waites et al., 1988).M. hominis is not visualizable by
gram stain due to its lack of a cell wall, and although it may grow on
standard aerobic or anaerobic bacterial culture plates, this method is in-
sensitive and requires highly experienced laboratory personnel to rec-
ognize colonies of M. hominis. M. hominis-speciﬁc culture may be
performed, but are not widely available, and even if they are available,
is not rapid. The route of acquisition of M. hominis in patients who un-
dergo cardiothoracic transplantation has not been deﬁned. In two
prior reports in Chest the authors speculated 1) the organism entered
the bloodstream (though blood cultures were negative) of a lung
transplant recipient who developed pleural and pulmonary infection
withM. hominis. These authors speculated manipulation of the urinary
tract with a Foley catheter elicited invasion of lung tissue damaged by
transplantation (Lyon et al., 1997) and 2) an 18 year old women devel-
oped diffuse alveolar hemorrhage following bone marrow transplant
due to unproven airway or urinary tract colonization (Kane et al.,
1994). Herein, we describe seven new cases ofM. hominis infection in
cardiothoracic transplant recipients and review the literature on the
topic. We highlight the unique clinical presentation of M. hominis in
this patient population and present evidence suggesting that this infec-
tion may be donor-transmitted.M. hominis should be considered in the
etiological diagnosis of surgical site infections, mediastinitis and
pleuritis after lung or heart-lung transplantation; use of M. hominis-
speciﬁc PCR may expedite diagnosis.
2. Methods
The study was reviewed and approved by the Mayo Clinic Institu-
tional Review Board (14-007214). Individual patient consent was not
needed.
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2.1. Case Detection
Using our heart and lung transplant database and chart review (be-
tween 1998 and July 2015) we found seven (among 182 lung trans-
plants and heart-lung performed and 453 heart transplants)
previously unreported cases of culture positiveM. hominis infection in
cardiothoracic transplant recipients (Table 1). In each case routine cul-
tures grewM. hominis and no other bacterial pathogenswere identiﬁed.
PCR forM. hominis (beginning January 2014), Ureaplasma urealyticum,
and Ureaplasma parvum (beginning January 2015) were requested
when suspected infection sites were gram stain negative, and early bac-
terial cultures were negative with the presence of white blood cells.
M. hominis, Ureaplasma urealyticum, and Ureaplasma parvum PCR were
speciﬁcally performed prospectively on all donor airway specimens be-
ginning in 2015. Importantly, in each case reported herein M. hominis
was the only infectious agent identiﬁed. None of these M. hominis
cases developed hyperammonemia and none of these cases tested pos-
itive for Ureaplasma sp. However, we have recently identiﬁed a single
case of donor bronchus which tested as M. hominis PCR negative and
Ureaplasma urealyticum PCR positive as well as a single case of donor
bronchus which tested as M. hominis PCR positive and Ureaplasma
urealyticum PCR negative. Both cases were treated prophylactically
without evidence of disease. AllM. hominis cases and donor surveillance
cases were reported to the host organ procurement organization as re-
quired by the Organ Procurement Transplant Network. Prior to 2009 all
patient received cytolytic induction, after 2009 only heart recipients re-
ceived cytolytic induction. All patients received intraoperative methyl-
prednisolone. Post-transplant immunosuppression is listed in Table 1.
2.2. Literature Review
PubMedwas queried beginning in 1950 forM. hominis infection and
cardiothoracic transplantation.
2.3. Surveillance Detection of M. hominis DNA in BAL Fluid from Non-
cardiothoracic Transplant Immunocompromised Patients
BAL samples submitted for detecting organisms commonly found in
immunocompromised hosts undergoing clinically indicated bronchos-
copy were tested forM. hominis DNA. We used a previously-described
real-time PCR assay targeting M. hominis tuf (Cunningham et al.,
2013). DNA was extracted on the MagNA Pure LC instrument using
the MagNA Pure total nucleic acid isolation kit (Roche Applied Science,
Indianapolis, IN).
3. Results
3.1. Patient Evaluation and Donor Characteristics
All patients received standard immunosuppression. All patients had
pre-transplant sputum cultures which were negative for M. hominis.
Routine perioperative bacterial prophylaxis included Vancomycin for
48 h and Cefepime for 48–72 h. Trimethoprim/sulfamethoxasole was
typically begun on post-operative day 2 or 3. Any additional bacterial
prophylaxis was based upon donor and recipient airway cultures. In
all cases clinical signs, including prolonged pleural effusion, prompted
routine bacterial and fungal cultures of suspected sites of infection.
Table 1
Summary of 7 Mayo Clinic cases ofMycoplasma hominis infection in thoracic transplant recipients.
Case
tran-plant
(year)
Age
(years)
Sex
Transplant
indication
Transplant type
Immune suppression
Signs or symptoms
(days after
transplant)
Clinical
presentation
Method used to diagnose
M. hominis infection
Surgical
management
Antimicrobial
therapy
Outcome
A (2000) 44M Secondary
pulmonary
hypertension
HL
ATG/CSA/AZA/Pred
Sternal site infection
with sternal
dehiscence (15)
Sternal
wound
infection
Culture-positive surgical
debridement specimens
Debridement
and
sternectomy
Doxycycline
and
ciproﬂoxacin
× 10 years
Recovered
B (2009) 69M Idiopathic
pulmonary
ﬁbrosis
SL
ATG/Tacro/AZA/Pred
Dyspnea, unilateral
pleural effusion (14)
Pleuritis Culture positive pleural
ﬂuid
Catheter
drainage of
pleural ﬂuid
Levoﬂoxacin
for 3 weeks
Recovered
C (2011) 41F Pulmonary
hypertension
HL
ATG/Tacro/Mycop/Pred
Dyspnea, cough with
progression to
circulatory shock in
48 h (19)
Mediastinitis
with aortic
anastomotic
leak
Culture positive
pericardial ﬂuid, periaortic
tissue and BAL ﬂuid
Mediastinal
debridement
(3)
Clindamycin
for 4 weeks
then
doxycycline
(lifelong)
Recovered
D (2014) 64M Idiopathic
pulmonary
ﬁbrosis
SL
Tacro/AZA/Pred
Dyspnea, loculated
pleural effusion (16)
Pleuritis PCR- and culture-positive
pleural ﬂuid
Thoracotomy
and
debridement
Levoﬂoxacin
and
doxycycline
for 6 weeks,
followed by
doxycycline
for 6 months
Slow
recovery with
multiple
subsequent
infectious
complications
E (2015) 64M Chronic
obstructive
lung disease
SL
Tacro/AZA/Pred
Fever, leukocytosis
and a loculated
hydropneumothorax
(7)
Pleuritis PCR- and culture-positive
pleural ﬂuid; culture
positive debridement
specimens (multiple)
Thoracotomy
and
debridement,
wound VAC
Doxycycline
(lifelong)
Recovered
F (2015) 70M Idiopathic
pulmonary
ﬁbrosis
SL (same donor as D)
Tacro/AZA/Pred
Dyspnea, and
loculated pleural
effusion (21)
Pleuritis PCR- and culture-positive
pleural ﬂuid;
culture-positive central
venous catheter tip
Pleural ﬂuid
aspiration
Doxycycline
(lifelong)
Recovered
G (2015) 63M Idiopathic
pulmonary
ﬁbrosis
BL
Tacro/Myco/Pred
Subcutaneous
emphysema (63)
Right
bronchial
anastomotic
leak
PCR positive from both
pretransplant donor
bronchi and recipient
pleural ﬂuid; culture
positive from both
pretransplant donor
brochi and later bronchial
anastomotic eschar
Delayed
bronchial
anastomotic
healing
Levoﬂoxacin
and
doxycycline
(lifelong)
Recovered
M, male; F, female; HL, heart-lung transplant; BL, bilateral lung transplant; SL, single lung transplant; BAL, bronchoalveolar lavage; ATG, antithymocyte globulin; Tacro, tracrolimus; AZA,
azathioprine; Pred, prednisone; Myco, mycophenolate mofetil.
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M. hominiswas consider etiologic if routine cultures were negative and
M. hominis was identiﬁed by culture or PCR in presumed sterile sites.
Donor characteristics are summarized in Table 2. Although our observa-
tions are limited to seven distinct donors among eight recipient cases
(including a previously reported caseWylam et al., 2013), several char-
acteristics are noted. The average donor agewas 19.7 years (16–23). Six
of seven donors had a history of, or tested positive for, drugs of abuse,
including methamphetamine and marijuana. In addition, 5 of 7 donors
were known tobacco users.
3.2. Literature Review
Our review of the literature since 1950 identiﬁed 15 cases of
M. hominis infection in lung, heart or heart-lung transplant recipients
(Table 3), one of which was reported from our institution (Wylam
et al., 2013). Including our seven new cases, the mean age of the 22 re-
cipients was 47.9 years with 72.7% being male. Pulmonary hyperten-
sion, chronic obstructive pulmonary disease (COPD) and pulmonary
ﬁbrosis were themost frequent indications for transplantation. Patients
developed symptoms a mean of 17.1 days (range 4–63 days) following
transplantation. Fever was reported in 8/22 (36%). Pleural/pericardial
effusion, chest wall/sternal wound infection, orM. hominis bacteremia
was evident in 13 (59%) and 12 (55%), and 2 (9%), respectively. All 13
patients with pleural effusions had positive pleural ﬂuid cultures for
M. hominis. Twelve (55%) patients hadM. hominis cultured from more
than one site;M. hominiswas isolated from BAL ﬂuid in seven cases.
3.3. Detection of M. hominis DNA in BAL Fluid from Immunocompromised
Patients
In 178 BAL samples obtained from random immunocompromised
non-cardiothoracic transplant patients submitted for detecting organ-
isms commonly found in immunocompromised hostsM. hominis DNA
was not detected in any specimen.
3.4. Assessment for Donor-derived Infection
In our Case B of culture provenM. hominis single lung transplant as-
sociated pleuritis, the donor's other lungwas transplanted into a 67 year
old female (not included in this report) at our institution who devel-
oped superﬁcial wound cellulitis, chest pain and a right-sided
hydropneumothorax in the second week post-surgery. A pleural pigtail
catheter was placed and routine bacterial cultures on standard media
were negative.M. hominis PCR testingwas not performed. However, im-
aging showed persistent pleural thickening with ﬂuorodeoxyglucose
uptake in the right thoracic cage. She received levoﬂoxacin for divertic-
ulitis and improved clinically. Together, this data suggest the possibility
of undiagnosedM. hominis infection.
In case G, the donor bronchus culture swab was PCR positive for
M. hominis. Levoﬂoxacin was given for 2 weeks and doxycycline (life-
long) in addition to standard prophylaxis with Vancomycin and Cefe-
pime. Recently, (data not included) we have prophylactically treated
one patient whose donor bronchus culture swab was PCR positive for
M. hominis and one patient who's donor bronchus culture swab was
PCR positive for Ureaplasma urealyticum. Each patient was treated
with doxycycline for 28 days.
Cases E and F (Table 1, Fig. 1) had received single lung transplants
from the samedonor and each case had transplant site speciﬁc infection.
Multilocus sequence typing (MLST) was performed on isolates recov-
ered from these two cases and two additional reference isolates (a clin-
ical isolate and the type strain ATCC 23114), using methods described
by Sogaard et al. (Sogaard et al., 2002). Brieﬂy, PCR was performed
targeting housekeeping genes, tuf, ftsY, hitB-hitL, uvrA and gap, followed
by bidirectional Sanger sequencing. Sequencing data were analyzed
(trimming and contig assembly) with the CLC Genomics Workbench
(CGW) version 8.0.3 (CLC bio, Cambridge, MA) sequence analysis mod-
ule. For each target, sequences were aligned and identities calculated
using the CGW alignment and tree module. Alignments of the house-
keeping genes were joined and a phylogenetic tree constructed using
the CGW alignment and tree module. Maximum-likelihood and neigh-
bor joining trees with Jukes-Cantor correction and bootstrap analysis
(1000 replicates) were constructed with the CGW software. Isolates re-
covered from cases D and E were indistinguishable by MLST, with no
base pair differences across the ﬁve sequenced housekeeping genes
(3094 bases). These results suggest common source infection, such as
donor-derived infection. No other patients on their hospital unit, other
hospital units, or under their surgeons care were infected byM. hominis.
4. Discussion
M. hominis infection in cardiothoracic transplant recipients has been
uncommonly reported. The true infection rate may be underestimated
in view of difﬁculties in detecting the organism in clinical specimens
and in the use of antibiotic prophylaxis and empiric antimicrobial regi-
mens, such asﬂuoroquinolones, that do targetM. hominis. Cardiothorac-
ic transplant patients sustain all of the risks for infection generally
encountered in the routine practice of cardiovascular surgery, including
Staphylococcus species, Pseudomonas, and Serratia, but fungi especially
Aspergillus species and Candida contribute importantly (Stinson and
Oyer, 1995). Donor transmission of infection remains important. Sur-
veillance cultures of donor and recipient, and antimicrobial prophylaxis
remain the cornerstone of infection prevention. In the report herein, we
note infection withM. hominis in the absence of other known infection.
The manifestations were often delayed after transplantation by several
weeks, and included pleuritis with cellulitis, trapped lung, delayed
Table 2
Donor characteristics associated with the cases described in table and our case described in Reference (Wylam et al., 2013).
Case Donor
age
(years)
Sex
Donor race Donor
serologies
Drug screen Other
drug
history
Tobacco Donor mechanism
of
death
A 22 F Caucasian CMV+/EBV+ Methampetamine, tricyclic antidepressant,
acetaminophen, aspirin
Alcohol No Drug overdose
B 23 M Hispanic CMV+/EBV+ Marajuana, ETOH Alcohol Yes CHI
C 19 M Caucasian CMV+/EBV+ Negative Marajuana Not known CHI
D/E 16 M African
American
CMV+/EBV+ Negative Marajuana Yes GSW to head
F 23 M Caucasian CMV−/EBV+ Negative Alcohol Yes,
chewing
CHI/MVA
G 19 F Caucasian CMV+/EBV+ Methampetamine Alcohol Yes CHI/MVA
Ref (Wylam et al.,
2013)
16 M African
American
CMV+/EBV+ Marajuana Alcohol Yes CHI/MVA
M, male; F, female; CMV, cytomegalovirus; EBV, Epstein-Barr virus; GSW, gun shot wound; CHI, closed head injury; MVA, motor vehicle accident.
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airway anastomotic healing, and aortic and sternal dehiscence. Treat-
ment included surgical intervention and long-term antibiotics.
M. hominis is not stainable by Gram stain and recognition of its
pinpoint-sized colonies requires experienced laboratory personnel.
BacT/ALERT and BACTEC media (used for blood cultures) contain sodi-
um polyanethol sulfonate, which may inhibit Mycoplasma growth
(Waites and Canupp, 2001), and growth may not exceed the threshold
value for positivity (Waites and Canupp, 2001). SelectiveM. hominis cul-
ture media may be useful but remain laborious and expensive.
Since the mid-1990s DNA probe methods using PCR to identify the
nucleotide sequences of M. hominis have been developed which seek
to avoid diagnostic time delays while offering the sensitivity and speci-
ﬁcity of conventional culturemethods (Yoshida et al., 2003). PCR assays
have been designed to target the glyceraldehyde-3-phosphate dehydro-
genase gene (gap) (Waites et al., 2009), yidC (Zhang and Wise, 1996),
theM. hominis 16S ribosomal RNA gene (Schwab et al., 2012), and, as
used herein, tuf (Cunningham et al., 2013). We previously reported (in
genitourinary specimens) a clinical sensitivity and speciﬁcity of 90.7%
Table 3
Literature review of thoracic transplant recipient infection withMycoplasma hominis.
Case
(Ref)
Age
(years)
Sex
Transplant
indication
Transplant
type
Signs or symptoms
(days after transplant)
Cultures positive
for M. hominis
Surgical
management
Antimicrobial
therapy
Outcome
1 (Hopkins et al., 2002) 52 M Bronchiectasis BL Bilateral pleural
effusions,
thoracotomy
dehiscence, bronchial
anastomostic
dehiscence (14)
Wound swab and
debrided tissue
Bronchial stent
placement
Clindamycin and
ciproﬂoxacin
followed by oral
doxycycline for
6 weeks
Recovered
2 (Hopkins et al., 2002) 55 M Ischemic
cardiomyopathy
H Sternal dehiscence,
fever (8)
Sternal wound
swab, pleural
ﬂuid
Surgical
debridement,
drainage
Ciproﬂoxacin and
doxcycline for
14 days
Recovered
3 (Hopkins et al., 2002) 21 M Dilated
cardiomyopathy
H Sternal wound
infection (14)
Sternal wound,
pericardial and
pleural ﬂuid
Surgical
debridement,
drains
Ciproﬂoxacin and
doxcycline
Recovered
4 (Hopkins et al., 2002) 17 M Becker
cardiomyopathy
H Sternal wound, pleural
effusion (21)
Sternal wound,
pericardial and
pleural ﬂuid
Surgical irrigation Ciproﬂoxacin and
doxcycline for
3 weeks
Recovered
5 (Lyon et al., 1997) 34 M APL and
pulmonary
hypertension
BL Pulmonary inﬁltrates,
pleural effusions (5)
Pleural ﬂuid,
bronchial brush
specimen, lung
biopsy
Surgical
debridement
Doxycycline for
4 weeks
Recovered, replased
M. hominis sternal
wound infection on
day 108
6 (Mitsani et al., 2010) 64 M Emphysema BL Tachycardia,
tachypnea (36)
Pericardial ﬂuid Pericardiocentesis Doxycycline for
6 week
Recovered
7 (Steffenson et al., 1987) 30 F Pulmonary
hypertension
HL Cough (3), unstable
sternum, fever (24)
Sternum, BAL Surgical
debridement
+ muscle ﬂap
Clindamycin and
doxycycline and
gentamicin;
duration
unknown
Died, day 69
post-transplant
8 (Steffenson et al., 1987) 43 F Pulmonary
hypertension
HL Dyspnea, pulmonary
inﬁltrates (13),
erythema sternal
tenderness (17)
Sternal wound,
BAL
Superﬁcial I&D
with wound
packing
Doxycycline and
clindamycin and
gentamicin
Died, day 37
post-transplant
9 (Boyle et al., 1993) 48 M Eisenmenger
syndrome
HL Unstable sternum,
fever (30)
Sternal wound Surgical
debridement
+ muscle ﬂap
over sternum
Doxycycline for
6 weeks
Relapse ofM. hominis
empyema seven
months later. Placed
on doxycycline
suppression
10 (Mossad et al., 1996) 41 M Cystic ﬁbrosis BL Sternal wound
drainage (22)
Sternal wound
culture
Surgical
debridement and
omental muscle
ﬂap
Erythromycin for
14 weeks
Recovered
11 (Gass et al., 1996) 65 M Alpha-1
antitrypsin
deﬁciency
BL Pulmonary inﬁltrates,
pleural effusion, fever
(7)
Pleural ﬂuid, BAL Not available Ciproﬂoxacin for
4 weeks
Recovered
12 (Gass et al., 1996) 50 M Emphysema SL Pleural effusion,
dyspnea (5)
Pleural ﬂuid None Ciproﬂoxacin for
4 weeks
Recovered
13 (Mcmahon et al.,
1990)
31 F Not available HL Sternal wound
drainage, fever (6)
BAL, sternal
wound culture
Debridement
+ muscle ﬂaps
Clindamycin and
doxycycline for
3 weeks
Dieda
14 (Mcmahon et al.,
1990)
43 F Not available HL Sternal wound
drainage, fever (13)
BAL, sternal
wound
Unknown Clindamycin and
doxycycline for
3 weeks
Diedb
15 (Wylam et al., 2013) 64 F Idiopathic
pulmonary
ﬁbosis
BL Confusion, fever,
pulmonary inﬁltrates,
coma,
hyperammon-emia
(4)
Catheter tip
(multiple
post-mortem
tissues PCR
positive for
M. hominis)
None Ciproﬂoxacin Died
M, male; F, female; HL, heart-lung transplant; BL, bilateral lung transplant; SL, single lung transplant; BAL, bronchoalveolar lavage; H, heart; APL, antiphospholipid antibody syndrome.
a After complications with rejection & respiratory failure. Cultures forM. hominiswere negative at that time.
b Developed an unstable sternum and CMV pneumonitis.
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(95% CI: 77.4%, 97.3%) and 99.2% (95% CI: 97.0%, 99.9%), respectively
(Cunningham et al., 2013). For the detection of M. hominis PCR tests
are faster than culture tests using media supplemented with arginine,
allowing the time to diagnosis to be reduced from two to ﬁve days to
b24 h (Abele-Horn et al., 1996). To date the Federal Drug Administra-
tionCenter for Devices and Radiologic Health has not approved a nucleic
acid based test for the detection of M. hominis. Thus, in the U.S. trans-
plant physician will need to consider reference laboratories to perform
PCR testing as well as dedicatedM. hominis cultures and empiric treat-
ment for suspected cases ofM. hominis infection.
The mode of acquisition of M. hominis in cardiothoracic transplant
recipients has been uncertain. Colonization rates of donors and recipi-
ents have hitherto been uncharacterized (Waites and Canupp, 2001).
Lacking the genes coding for a cell wall appears to limitM. hominis to a
parasitic and saprophytic existence. There are no known natural reser-
voirs forM. hominis though it has been recovered from randompublic toi-
let rims (Potasman et al., 1999). M. hominis is part of the normal
urogenital ﬂora, suggesting a potential endogenous source. Thus, others
have speculated without data that M. hominis enters the bloodstream
from manipulation of the urethra by Foley catheter placement in colo-
nized recipients (Lyon et al., 1997). This rationale is supportedby theﬁnd-
ing ofM. hominis sternal wound infection in non-immunocompromised
patients undergoing coronary artery bypass graftingwithout transplanta-
tion (Steffenson et al., 1987). A case cluster involving four cases alluded to
a common environmental source (Hopkins, 2001; Hopkins et al., 2002),
with a suspicion of nosocomial transmission in the four reported cases
ofM. hominis infection occurring over three weeks in the same hospital
(Hopkins et al., 2002).
Primary immunodeﬁciencies are associated with sepsis and septic
arthritis due toM. hominis. Most reports include patients with common
variable immunodeﬁciency or X-linked agammaglobulinemia (Bloom
et al., 2008). Though postpartum septicemia caused by M. hominis
may be due to genitourinary bacterial translocation (Tully and Smith,
1968), immunodeﬁciency cases commonly are not associated with uri-
nary tract manipulation. This suggests that dissemination ofM. hominis
maybe fromacquired from sites outside the genitourinary tract. Though
the mechanism(s) required for immunocompetence againstM. hominis
is not clear, we note that in all of our cases pre-transplant immunoglob-
ulin IgA, IgM, IgG and IgG subclasses were determined and values were
normal (data not shown) in all cases.
The colonization rate of heart and lung transplant donors with
M. hominis is not known andmay be different from the general popula-
tion.M. hominismay induce exudative pharyngitis (Mufson et al., 1965)
and older reports using culture suggest reported it to be recoverable
from the respiratory secretions of 1–3% of healthy persons (Hendley
and Jordan, 1968) and of ≤8% of persons with chronic respiratory dis-
ease (Mufson, 1983). Thus, there is the possibility of transmission relat-
ed to donor airway colonization, or organ contamination during organ
procurement. Donor oral sexual practice may be a risk factor for
M. hominis airway colonization as oral sex has been noted as an impor-
tant route of transmission for M. hominis (Edwards and Carne, 1998;
Sackel et al., 1979). Our review of the literature (Table 3, cases 11 and
12) describes two recipients who had received lungs from the same
donor, supporting the possibility of a donor-derived infection (Gass
et al., 1996). Two of their cases (heart and bilateral lung recipients)
shared the same donor, although cultures of donor bronchus did not
grow M. hominis; it is unknown whether M. hominis-speciﬁc cultures
were performed.
Our observations in cases B, E, F, and G suggest that in cardiothoracic
transplant recipients, donor-derived acquisition of M. hominis is possi-
ble. The likelihood that the disease is of donor origin fulﬁlls the term
probable donor transmission established by Project NOTIFY (Garzoni
and Ison, 2011) as (1) we cannot exclude pre-transplant disease in the
recipient; but (2) the disease was documented in more than one recip-
ient (cases E and F) and (3) we provide epidemiologic evidence
reporting that in cases D and E there was strain as the isolates were in-
distinguishable via MLST. Due to a lack of residual specimen, it was not
possible to isolate the organism from the donor respiratory tract via cul-
ture or detect it by PCR. However, in case G, a donor bronchus swab (the
ﬁrst swab we tested prospectively) tested positive PCR for M. hominis.
Our surveillance data showing the absence of M. hominis DNA by PCR
in the BAL samples of unselected immunocompromised hosts suggests
that a positive test should be considered signiﬁcant in the appropriate
clinical context. Further studies are needed to evaluate the correlation
between clinical infection in cardiothoracic transplant recipients and
M. hominis positivity in the donor respiratory tract.
We have previously reported detection ofM. hominis infection in a
case of post-lung transplant hyperammonemia (Wylam et al., 2013);
the patient had a positive central venous blood culture for M. hominis
and PCR and immunoﬂuorescence detection of M. hominis in multiple
post-mortem tissues. Follow-up testing showed the patient to have
been co-infected with Ureaplasma parvum (Bharat et al., 2015). In
follow-up studies, Ureaplasma species, both U. parvum and Ureaplasma
urealyticum (without M. hominis) were shown to be associated with
hyperammonemia in ﬁve other lung transplant recipients (Bharat
et al., 2015). Therefore, whether or not M. hominis plays a role in
hyperammonemia in lung transplant patients is unclear. In our cases
D, E, F, and G, blood ammonia determined and was not elevated, sug-
gesting that non-systemic M. hominis infection is insufﬁcient to cause
hyperammonemia in lung transplant recipients.
AsM. hominis does not produce peptidoglycan, cell wall active anti-
biotics likeβ-lactams and vancomycin, commonly used post-transplant,
are ineffective.Moreover,M. hominis does not require folate and is resis-
tant to folate antagonists (such as trimethoprim/sulfamethoxazole); it
is also resistant to aminoglycosides (Sielaff et al., 1996). M. hominis is
naturally resistant to 14- and 15-membered macrolides, including
erythromycin and azithromycin, but is usually susceptible to
clindamycin (Furneri et al., 2000). One study tested 110 clinical isolates
Fig. 1. Phylogenetic tree based onmultilocus sequence typing showing theM. hominis isolates from case D (MBRL 1161) and case E (MBRL 1162) to be indistinguishable. The spine isolate
represents an isolated from a contemporaneous clinical case ofM. hominis spinal osteomyelitis; ATCC 23114 is the reference strain.
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of M. hominis and found levoﬂoxacin to be inhibitory in all instances,
with anMIC90 of 0.19 μg/ml (Samra et al., 2002). Treatment recommen-
dations forM. hominis infection therefore include tetracyclines (doxycy-
cline is preferred), ﬂuoroquinolones and/or clindamycin. Importantly,
tetracyclines, ﬂuroquionolones and clindamycin are not typically in-
cluded in standard post-transplant prophylactic regimens, nor are
they typically included in empiric therapy regimens for surgical site in-
fections. The tet(M) determinant confers tetracycline (and doxycycline)
resistance; the prevalence of tetracycline resistance inM. hominis varies
by geographic location and may be as high as 30% (Pogodina, 1975;
Samra et al., 2002; Ye et al., 2014). Although susceptibility testing
should be used when available, in the absence of deﬁnitive evidence,
we suggest that combination therapy with a ﬂuoroquinolone and doxy-
cycline may be a preferred regimen for establishedM. hominis infection
in cardiothoracic transplant recipients, given the possibility of tetracy-
cline resistance and the potential for selection of ﬂuoroquinolone resis-
tance with ﬂuoroquinolone monotherapy (Bebear et al., 2003). The
optimal duration of therapy for M. hominis infection in cardiothoracic
transplant recipients is not known.
In summary,M. hominis is a cause of cardiothoracic transplant infec-
tion, presenting with pleuritis, surgical site infection, and/or
mediastinitis. We provide evidence that this infection is probably
donor-derived. Rapid PCR is an expedient method of detection, used
to diagnose four of seven of the cases reported, but does not replace cul-
turing the organism to determine the susceptibility proﬁle. Our current
approach is to perform routine PCR for M. hominis, Ureaplasma
urealyticum and U. parvum and to perform bacterial culture all donor
airways. We perform the same PCR tests on any suspected surgical
site infection which is gram stain negative. In addition, we reﬂexively
culture any PCR-positive specimens (e.g., pleural ﬂuid) from cardiotho-
racic transplant recipients for the purpose of susceptibility testing. Cur-
rently, most antibiotic prophylaxis regimens, and regimens for
empirical therapy of post-transplant infectious complications do not
coverM. hominis. Prospective studies are needed to assess the correla-
tion between donor airway positivity forM. hominis and clinical infec-
tion in transplant recipients.
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